Harrow, Inc. Files 8-K: Material Agreement, Equity Sales
Ticker: HROW · Form: 8-K · Filed: Sep 26, 2025 · CIK: 1360214
| Field | Detail |
|---|---|
| Company | Harrow, INC. (HROW) |
| Form Type | 8-K |
| Filed Date | Sep 26, 2025 |
| Risk Level | medium |
| Pages | 5 |
| Reading Time | 6 min |
| Key Dollar Amounts | $0.001, $4.3 million, $87.2 million, $100.0 million, $1.0 billion |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-definitive-agreement, equity-sales, corporate-action
Related Tickers: HROW
TL;DR
Harrow Inc. (HROW) filed an 8-K on 9/24/25 detailing a material definitive agreement and equity sales.
AI Summary
On September 24, 2025, Harrow, Inc. entered into a material definitive agreement related to its senior notes. The company also reported on unregistered sales of equity securities and other events, including financial statements and exhibits. Harrow, Inc. is a pharmaceutical preparations company based in Nashville, TN.
Why It Matters
This filing indicates significant corporate actions by Harrow, Inc., including a material definitive agreement and equity sales, which could impact its financial structure and stock performance.
Risk Assessment
Risk Level: medium — The filing involves material definitive agreements and unregistered sales of equity, which can introduce financial and regulatory risks.
Key Numbers
- 2834 — SIC Code (Pharmaceutical Preparations industry)
Key Players & Entities
- HARROW, INC. (company) — Filer
- September 24, 2025 (date) — Date of earliest event reported
- Nashville, TN (location) — Company Business Address
- Harrow Health, Inc. (company) — Former Company Name
- Imprimis Pharmaceuticals, Inc. (company) — Former Company Name
- Transdel Pharmaceuticals Inc (company) — Former Company Name
FAQ
What is the nature of the material definitive agreement entered into by Harrow, Inc. on September 24, 2025?
The filing indicates an 'Entry into a Material Definitive Agreement' as an item information, but the specific details of the agreement are not provided in this excerpt.
What type of equity securities were sold unregistered by Harrow, Inc.?
The filing lists 'Unregistered Sales of Equity Securities' as an item information, but the specific type and details of these securities are not elaborated in this excerpt.
What are the former names of Harrow, Inc. mentioned in the filing?
The filing lists Harrow Health, Inc. (name change 20181228), Imprimis Pharmaceuticals, Inc. (name change 20120301), and Transdel Pharmaceuticals Inc (name change 20070912) as former names.
What is Harrow, Inc.'s fiscal year end?
Harrow, Inc.'s fiscal year ends on December 31st.
What is the SEC file number for Harrow, Inc.'s 8-K filing?
The SEC file number for this 8-K filing is 001-35814.
Filing Stats: 1,529 words · 6 min read · ~5 pages · Grade level 13.2 · Accepted 2025-09-26 07:05:55
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value per share HROW The Nasdaq
- $4.3 million — n initial cash payment of approximately $4.3 million at closing, and contingent consideratio
- $87.2 million — gregate amount in cash of approximately $87.2 million. Upon receipt of pass-through status
- $100.0 million — nnual net sales milestones ranging from $100.0 million to $1.0 billion per year, the Company s
- $1.0 billion — lestones ranging from $100.0 million to $1.0 billion per year, the Company shall make one-ti
- $261.0 million — aggregate may total up to approximately $261.0 million if all annual net sales milestones are
Filing Documents
- form8-k.htm (8-K) — 58KB
- ex99-1.htm (EX-99.1) — 30KB
- ex99-1_001.jpg (GRAPHIC) — 3KB
- 0001493152-25-015054.txt ( ) — 314KB
- hrow-20250924.xsd (EX-101.SCH) — 4KB
- hrow-20250924_def.xml (EX-101.DEF) — 26KB
- hrow-20250924_lab.xml (EX-101.LAB) — 36KB
- hrow-20250924_pre.xml (EX-101.PRE) — 25KB
- form8-k_htm.xml (XML) — 6KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. HARROW, INC. Dated: September 26, 2025 By: /s/ Andrew R. Boll Andrew R. Boll President and Chief Financial Officer